Pluri Inc. — SEC Form D Filing

Pluri Inc. filed an SEC Form D on September 4, 2026, reporting $3.68M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 4, 2026
Amount reported
$3.68M
Round stage
Series A because a $3.6 million raise represents an early-stage institutional round typical for advancing preclinical biotech assets toward clinical trials.
Industry
Biotechnology
Website
https://pluri-biotech.com

What the company does

Exemption: Rule 506(b). Incorporated: NEVADA

Problem

Developing scalable, consistent, and high-quality pluripotent stem cell therapies is hindered by complex manufacturing processes and high production costs.

Solution

Pluri designs and manufactures standardized, clinical-grade pluripotent stem cell platforms to accelerate the development of regenerative medicine therapies.

Why now

Recent regulatory advancements in cell therapy approvals and breakthroughs in CRISPR-based gene editing have surged the demand for reliable, off-the-shelf cellular starting materials.

Source: SEC EDGAR Form D filing